Drug intelligence / Profile preview

miR-1283 inhibitor

Development stage
Preclinical
Lead developer
Brown University
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous, Intravenous, Parenteral
01

Overview

miR-1283 inhibitor is a synthetic antisense oligonucleotide designed to sequence-specifically bind and sequester microRNA-1283 (miR-1283), thereby preventing it from regulating its target messenger RNAs. In preclinical neuro-oncology research, miR-1283 has been identified as a potential biomarker that is significantly under-expressed in the serum of patients with glioblastoma and other brain tumors. Experimental inhibition of miR-1283 in glioblastoma stem cells (GSCs) using these inhibitors has been shown to augment cell growth, viability, and self-renewal, suggesting that the loss of miR-1283 expression may contribute to tumor progression. These inhibitors are primarily utilized as research tools to elucidate the functional role of miR-1283 in cancer biology and stem cell maintenance.

Other names
microRNA-1283 inhibitormicroRNA1283 inhibitormicroRNA 1283 inhibitoranti-miR-1283anti-miR1283anti-miR 1283antagomir-1283antagomir1283antagomir 1283
02

Targets

miR-1283 (microRNA-1283)

Beyond the preview

Go deeper on miR-1283 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-1283 inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call